FINAL REFUSAL - MAILED
mailed
on 11 Dec 2024
Last Applicant/ Owned by
8700 West Bryn Mawr, Suite 600S
Chicago
IL
60631
Serial Number
98173706 filed on 11th Sep 2023
Registration Number
N/A
Correspondent Address
Eric R. Moran
Filing Basis
1. intent to use
2. intent to use current
Disclaimer
NO DATA
ANIVIO
research and development of biologics, biosimilars, pharmaceuticals, and self-replicating mRNA; providing information in the field of scientific and medical research related to biologics, biosimilars, pharmaceuticals, and self-replicating mRNA providing medical information; providing health information house mark for a full line of biologic, biosimilar, and pharmaceutical preparations; biologics Read More
Classification Information
Class [044]
Medical, Beauty & Agricultural Services
providing medical information; providing health information
First Use Date in General
N/A
First Use Date in Commerce
N/A
Class [042]
Computer & Software Services & Scientific Services
research and development of biologics, biosimilars, pharmaceuticals, and self-replicating mRNA; providing information in the field of scientific and medical research related to biologics, biosimilars, pharmaceuticals, and self-replicating mRNA
First Use Date in General
N/A
First Use Date in Commerce
N/A
Class [005]
Pharmaceutical Products
house mark for a full line of biologic, biosimilar, and pharmaceutical preparations; biologics; biosimilars; pharmaceuticals; biologic, biosimilar, and pharmaceutical preparations; biologic, biosimilar, and pharmaceutical products; anti-TNF alpha antibodies for medical purposes; monoclonal antibodies for medical purposes; anti-inflammatories; anti-inflammatory biologic, biosimilar, and pharmaceutical preparations, namely, anti-inflammatory preparations; biologic, biosimilar, and pharmaceutical preparations for the treatment of lung diseases and disorders; biologic, biosimilar, and pharmaceutical preparations for the treatment of inflammatory disorders; biologic, biosimilar, and pharmaceutical preparations for the treatment of pulmonary sarcoidosis; biologic, biosimilar, and pharmaceutical preparations for the treatment of sarcoidosis; biologic, biosimilar, and pharmaceutical preparations to reduce or prevent granulomas; biologic, biosimilar, and pharmaceutical preparations to reduce or prevent fibrosis; biologic, biosimilar, and pharmaceutical preparations, namely, biopharmaceutical preparations based on human monoclonal antibodies for the treatment of inflammatory diseases and disorders; self-replicating mRNA; pharmaceutical preparations containing self-replicating mRNA; pharmaceutical preparations containing self-replicating mRNA for the treatment of lung diseases and disorders, inflammatory disorders, pulmonary sarcoidosis, sarcoidosis; pharmaceutical preparations containing self-replicating mRNA to reduce or prevent granulomas; pharmaceutical preparations containing self-replicating mRNA to reduce or prevent fibrosis
First Use Date in General
N/A
First Use Date in Commerce
N/A
Mark Details
Serial Number
No 98173706
Mark Type
No Service Mark
Attorney Docket Number
No 23-1269-US
44D Filed
No
44D Current
No
44E filed
No
44E Current
No
66A Filed
No
66A Current
No
Current Basis
No
No Basis
No
Legal History
| Status Date | Action Taken |
|---|---|
| 11th Dec 2024 | NOTIFICATION OF FINAL REFUSAL EMAILED |
| 11th Dec 2024 | FINAL REFUSAL WRITTEN |
| 11th Dec 2024 | FINAL REFUSAL E-MAILED |
| 06th Nov 2024 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| 06th Nov 2024 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| 06th Nov 2024 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| 06th Aug 2024 | APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED |
| 06th Aug 2024 | APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED |
| 06th May 2024 | ASSIGNED TO EXAMINER |
| 06th May 2024 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |